New epitope peptides derived from hepatitis C virus (HCV) 2a which have the capacity to induce cytotoxic t lymphocytes in HLA-A2+ HCV-infected patients

Microbiology and Immunology

Volumn 50, Issue 11, 2006, Pages 857-865

  Wang, Yi ^a,c   Takao, Yukari ^a,b   Harada, Mamoru ^a,b   Yutani, Shigeru ^b   Ide, Tatsuya ^b   Sata, Michio ^a,b   Itoh, Kyogo ^a,b   Yamada, Akira ^a  

^a KURUME UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JILIN UNIVERSITY   (China)

Author keywords

CTL; HCV; Peptide; Vaccine

Indexed keywords

EPITOPE; HLA A2 ANTIGEN; VACCINE;

ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOTHERAPY; IN VITRO STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN ANALYSIS; PROTEIN BINDING;

HEPATITIS C VIRUS;

EID: 33751264618     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2006.tb03861.x     Document Type: Article

References (32)

1. Aebischer, T., Moskophidis, D., Rohrer, U.H., Zinkernagel, R.M., and Hengartner, H. 1991. In vitro selection of lymphocytic choriomeningitis virus escape mutants by cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 88: 11047-11051.
2. Alter, M.J., Margolis, H.S., Krawczynski, K., Judson, F.N., Mares, A., Alexander, W.J., Hu, P.Y., Miller, J.K., Gerber, M.A., Sampliner, R.E., et al. 1992. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N. Engl. J. Med. 327: 1899-1905.
3. Bukh, J., Miller, R.H., and Purcell, R.H. 1995. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin. Liver Dis. 15: 41-63.
4. Carbone, F.R., Moore, M.W., Sheil, J.M., and Bevan, M.J. 1988. Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides. J. Exp. Med. 167: 1767-1779.
5. Cerny, A., Ferrari, C., and Chisari, F.V. 1994. The class I-restricted cytotoxic T lymphocyte response to predetermined epitopes in the hepatitis B and C viruses. Curr. Top. Microbiol. Immunol. 189: 169-186.
6. Cerny, A., McHutchison, J.G., Pasquinelli, C., Brown, M.E., Brothers, M.A., Grabscheid, B., Fowler, P., Houghton, M., and Chisari, F.V. 1995. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J. Clin. Invest. 95: 521-530.
7. Chisari, F.V. 1997. Cytotoxic T cells and viral hepatitis. J. Clin. Invest. 99: 1472-1477.
8. + population. Science 260: 98-100.
9. Gotch, F., Rothbard, J., Howland, K., Townsend, A., and McMichael, A. 1987. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature 326: 881-882.
10. + T cells with viral clearance in acute hepatitis C. J. Infect. Dis. 181: 1528-1536.
11. Gulukota, K., and DeLisi, C. 1996. HLA allele selection for designing peptide vaccines. Genet. Anal. 13: 81-86.
12. Huy, T.T., and Abe, K. 2004. Molecular epidemiology of hepatitis B and C virus infections in Asia. Pediatr. Int. 46: 223-230.
13. Imawari, M., Nomura, M., Kaieda, T., Moriyama, T., Oshimi, K., Nakamura, I., Gunji, T., Ohnishi, S., Ishikawa, T., Nakagama, H., et al. 1989. Establishment of a human T-cell clone cytotoxic for both autologous and allogeneic hepatocytes from chronic hepatitis patients with type non-A, non-B virus. Proc. Natl. Acad. Sci. U.S.A. 86: 2883-2887.
14. Kanai, K., Kako, M., and Okamoto, H. 1992. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 339: 1543.
15. Kato, T., Date, T., Miyamoto, M., Furusaka, A., Tokushige, K., Mizokami, M., and Wakita, T. 2003. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125: 1808-1817.
16. Kiyosawa, K., Sodeyama, T., Tanaka, E., Gibo, Y., Yoshizawa, K., Nakano, Y., Furuta, S., Akahane, Y., Nishioka, K., Purcell, R.H., et al. 1990. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12: 671-675.
17. Koziel, M.J., Dudley, D., Wong, J.T., Dienstag, J., Houghton, M., Ralston, R., and Walker, B.D. 1992. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J. Immunol. 149: 3339-3344.
18. Maeda, Y., Hida, N., Niiya, F., Katagiri, K., Harada, M., Yamana, H., Kamura, T., Takahashi, M., Sato, Y., Todo, S., and Itoh, K. 2002. Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients. Br. J. Cancer 87: 796-804.
19. McHutchison, J.G., Gordon, S.C., Schiff, E.R., Shiffman, M.L., Lee, W.M., Rustgi, V.K., Goodman, Z.D., Ling, M.H., Cort, S., and Albrecht, J.K. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339: 1485-1492.
20. Mondelli, M., Vergani, G.M., Alberti, A., Vergani, D., Portmann, B., Eddleston, A.L., and Williams, R. 1982. Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J. Immunol. 129: 2773-2778.
21. Naumov, N.V., Mondelli, M., Alexander, G.J., Tedder, R.S., Eddleston, A.L., and Williams, R. 1984. Relationship between expression of hepatitis B virus antigens in isolated hepatocytes and autologous lymphocyte cytotoxicity in patients with chronic hepatitis B virus infection. Hepatology 4: 63-68.
22. Nelson, D.R., Marousis, C.G., Ohno, T., Davis, G.L., and Lau, J.Y. 1998. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology 28: 225-230.
23. Rehermann, B., Chang, K.M., McHutchinson, J., Kokka, R., Houghton, M., Rice, C.M., and Chisari, F.V. 1996. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J. Virol. 70: 7092-7102.
24. Rehermann, B., and Chisari, F.V. 2000. Cell mediated immune response to the hepatitis C virus. Curr. Top. Microbiol. Immunol. 242: 299-325.
25. Shirai, M., Akatsuka, T., Pendleton, C.D., Houghten, R., Wychowski, C., Mihalik, K., Feinstone, S., and Berzofsky, J.A. 1992. Induction of cytotoxic T cells to a cross-reactive epitope in the hepatitis C virus nonstructural RNA polymerase-like protein. J. Virol. 66: 4098-4106.
26. Takao, Y., Yamada, A., Yutani, S., Sata, M., and Itoh, K. 2004. Antibody reactive to a hepatitis C virus (HCV)-derived peptide capable of inducing HLA-A2 restricted cytotoxic T lymphocytes is detectable in a majority of HCV-infected individuals without HLA-A2 restriction. Microbiol. Immunol. 48: 507-517.
27. Tong, M.J., el-Farra, N.S., Reikes, A.R., and Co, R.L. 1995. Clinical outcomes after transfusion-associated hepatitis C. N. Engl. J. Med. 332: 1463-1466.
28. Tsubota, A., Chayama, K., Ikeda, K., Yasuji, A., Koida, I., Saitoh, S., Hashimoto, M., Iwasaki, S., Kobayashi, M., and Hiromitsu, K. 1994. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 19: 1088-1094.
29. van den Hoff, M.J., Moorman, A.F., and Lamers, W.H. 1992. Electroporation in 'intracellular' buffer increases cell survival. Nucleic Acids Res. 20: 2902.
30. Ward, S., Lauer, G., Isba, R., Walker, B., and Klenerman, P. 2002. Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin. Exp. Immunol. 128: 195-203.
31. Zein, N.N. 2000. Clinical significance of hepatitis C virus genotypes. Clin. Microbiol. Rev. 13: 223-235.
32. Zein, N.N., Rakela, J., Krawitt, E.L., Reddy, K.R., Tominaga, T., and Persing, D.H. 1996. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann. Intern. Med. 125: 634-639.